Press release
September 10, 2026
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
In8bio, Inc. (INAB)
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and